Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Share-based Compensation (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Share-based Compensation data on record, last reported at $4.4 million in Q4 2020.

  • For Q4 2020, Share-based Compensation rose 612.38% year-over-year to $4.4 million; the TTM value through Dec 2020 reached $9.4 million, changed N/A, while the annual FY2024 figure was $26.3 million, 35.39% down from the prior year.
  • Share-based Compensation reached $4.4 million in Q4 2020 per KLRS's latest filing, up from $3.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.4 million in Q4 2020 and bottomed at $492000.0 in Q2 2020.